CollPlant 6-K Reports 2023 Shareholder Letter

Ticker: CLGN · Form: 6-K · Filed: Feb 15, 2024 · CIK: 1631487

Sentiment: neutral

Topics: regulatory-filing, shareholder-communication, press-release

TL;DR

**CollPlant filed a 6-K today, February 15, 2024, reporting a shareholder letter issued exactly one year ago, on February 15, 2023.**

AI Summary

CollPlant Biotechnologies Ltd. filed a Form 6-K on February 15, 2024, to report a press release that was issued on February 15, 2023. The press release was titled "CollPlant Issues Letter to Sharehold", indicating communication with its investors. This administrative filing informs the SEC about the company's past public disclosure regarding its shareholders.

Why It Matters

This filing indicates CollPlant's formal communication with its shareholders, which could contain important updates on company strategy or performance. Investors would need to review the actual letter from February 15, 2023, to understand its full implications.

Risk Assessment

Risk Level: medium — The filing itself is administrative and does not contain information to assess specific financial or operational risks; the content of the referenced shareholder letter is not provided.

Key Numbers

Key Players & Entities

FAQ

What type of SEC filing is this document?

This document is a Form 6-K, which is a report of a foreign private issuer.

Which company filed this 6-K report?

CollPlant Biotechnologies Ltd. filed this 6-K report.

When was this 6-K report filed with the SEC?

This 6-K report was filed on February 15, 2024.

What event is CollPlant Biotechnologies Ltd. reporting in this 6-K?

CollPlant Biotechnologies Ltd. is reporting that it issued a press release on February 15, 2023.

What was the title of the press release mentioned in the filing?

The press release was entitled "CollPlant Issues Letter to Sharehold".

Filing Stats: 201 words · 1 min read · ~1 pages · Grade level 12.3 · Accepted 2024-02-15 08:19:29

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. COLLPLANT BIOTECHNOLOGIES LTD. Date: February 15, 2024 By: /s/ Eran Rotem Name: Eran Rotem Title: Deputy CEO and Chief Financial Officer 2

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing